title: Disease-related changes in TRPV1 expression and its implications for drug development.
abstract: The transient receptor potential vanilloid 1 (TRPV1) channel has been a topic of great interest, since its discovery in 1997. It is a homotetrameric non-selective cation channel predominantly expressed in a population of sensory neurons and its involvement in different modalities of pain has been extensively studied. However, TRPV1 has also been shown to be expressed in non-sensory neurons and non-neuronal cells. TRPV1 is considered as a potential target for drug development, based on its tissue distribution and its role in physiological functions. Here, we summarize the evidences for disease-related alterations in TRPV1 expression and function and review the current perspectives for the therapeutic potential of TRPV1 agonists and antagonists in the treatment of a wide range of diseases.
authors.affiliation: Department of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL 62702, USA. lpremkumar@siumed.edu
authors.forename: Louis S
authors.initials: LS
authors.lastname: Premkumar
authors.forename: Mahendra
authors.initials: M
authors.lastname: Bishnoi
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D004194:Disease; D055808:Drug Discovery; D006801:Humans; D010146:Pain / Q000188:drug therapy / Q000378:metabolism; D050916:TRPV Cation Channels / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D050916:TRPV Cation Channels; C494484:TRPV1 receptor